What is OncoTRACE?

OncoTRACE is a new genomic study that allows detecting tumour mutations present in the blood (circulating tumour DNA) to quantify and monitor residual disease after treatment, identify new resistance mutations and detect tumour relapse before imaging techniques. This objective is achieved by monitoring specific variants detected in the tumour and analysing new variants associated with sensitivity and resistance to targeted treatments.

Why OncoTRACE?

This study offers important individual information regarding the development and progression of the tumour and a more consistent prediction of response.
Thanks to OncoTRACE the oncologist will have valuable information about the effectiveness of the treatment he has selected for his patient, before the classical imaging techniques. Coverage 15,000 X. Sensitivity 99.9%. Specificity 99%.

Gene Panel

How does it works?

Being a personalized monitoring study, it is necessary that previously an OncoDEEP / OncoSRAT & GO study has been carried out in order to track the detected variants, in addition to analysing the panel of 40 genes that OncoTRACE possesses, between 12 and 15 detected variants will be added in the tumour.

NOTE: this personalized monitoring study can also be performed from other NGS analyses performed on the patient in which positive results have been obtained (alterations detected).

OncoTRACE consists of blood tests spaced in time approximately every 2-3 months (depending on the routine of visits and other conditions specific to the type of cancer the patient considers the oncologist).

During this period, by means of the analysis of the circulating tumour DNA, we follow those specific mutations / variants, measuring their relative abundance (their increase or decrease) and also monitoring the appearance of new ones that could be associated with resistance to treatment or sensitivity to a new one.


In partnership with: